The FDA has approved a new indication for adalimumab (Humira; Abbott Laboratories) for the treatment of moderate-to-severe ulcerative colitis in adults, to control ulcerative colitis when immunosuppressant medicines, such as corticosteroids, azathioprine, and 6-mercaptopurine, have not worked.
By Neil Canava Developing new strategies for the prevention of osteoarthritis (OA) and its significant clinical burden is largely based on better understanding of the mechanism of OA disease and identification of potential biomarkers that may be involved in the progressive deterioration of the joints, including knee and hip.
By Jennifer Kirschenbaum, Esq, and Erica Youngerman, Esq As healthcare reform changes the face of medical practice as we know it, certain initiatives are likely to play a prominent role in emerging practice structures. Among the programs predicted to take center stage are those offered by Medicare’s Shared Savings Program, in particular, accountable care organizations (ACOs).
By David Hawk Berlin, Germany—Results of an analysis presented by Chureen T. Carter, PharmD, MS, Associate Director of Health Economics and Outcomes Research at Janssen Scientific Affairs, Horsham, PA, and colleagues at the 2012 European League Against Rheumatism Congress indicate that during the time period of the introduction of biologic agents for the treatment of psoriatic arthritis, the direct healthcare costs related to psoriatic arthritis management rose from approximately $3500 annually to an annual expenditure exceeding $16,000.
By Alicia Ault Washington, DC—In 2013 and going forward, employers are likely to increasingly rely on direct contracting with physicians and using other means to steer patients to certain physicians in an effort to bring employee benefit costs in line, according to a new survey.
By Ruth Linné Lander, FACMPE Practice Administrator, Columbus Oncology & Hematology Associates, O I am going to start this business article with something personal. Decades ago I read a book that had a very good chapter on personal time management. I have followed one tip in this chapter ever since. In summary: pick the 5 outfits you want to wear Monday through Friday of your workweek during the current season.
TNF Blockers Increase the Risk for Herpes Zoster Infection in Patients with Inflammatory Rheumatic Disease
For moderate-to-severe disease, abatacept preferred as second agent By Rosemary Frei, MSc Results of a new study indicate that the most efficacious and cost-effective sequential treatment strategy of biologic agents, when one agent is insufficient, for people with moderate-to-severe rheumatoid arthritis (RA) includes abatacept (ABA) rather than rituximab (RTX) as the second agent in the sequence.
By Jennifer Kirschenbaum, Esq, and Erica Youngerman, Esq Unexpected and unwanted oversight is becoming a more frequent element of practice, making it imperative that you understand current investigation and audit initiatives, and how to prepare and protect your practice.
Page 3 of 4
Results 21 - 30 of 36
Results 21 - 30 of 36